<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNITED STATES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">FORM 8-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):&#9;<U>February
2, 2012</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESPONSE
GENETICS, INC.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
</U></B></FONT>(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border-bottom: windowtext 1pt solid; text-align: center; font-weight: bold">Delaware</TD>
    <TD STYLE="width: 1%; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: windowtext 1pt solid; text-align: center; font-weight: bold">000-1124608</TD>
    <TD STYLE="width: 1%; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: windowtext 1pt solid; text-align: center; font-weight: bold">11-3525548</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(IRS Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">jurisdiction of</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Number)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Identification No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">incorporation)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>1640 Marengo St., 6th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Los Angeles, California 90033</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(323) 224-3900</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s<BR>
 principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&#9;<U>Not Applicable<BR>
</U></B>&#9;(Former name or former address, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Wingdings; margin: 0 0 0 43pt; text-indent: -23pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-indent: 0in; font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="width: 4%; text-indent: 0in; font-family: Wingdings">&uml;</TD>
    <TD STYLE="width: 92%; text-indent: 0in">Written communications pursuant to Rule 425 under the Securities Act&nbsp;(17 CFR 230.425)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&uml;</TD>
    <TD STYLE="text-indent: 0in">Soliciting material pursuant to Rule 14a-12 under the Exchange Act&nbsp;(17 CFR 240.14a-12)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&uml;</TD>
    <TD STYLE="text-indent: 0in">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; font-family: Wingdings">&uml;</TD>
    <TD STYLE="text-indent: 0in">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43pt; text-indent: -23pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 1.01 Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On February 2, 2012, Response Genetics, Inc. (the &ldquo;Company&rdquo;)
entered into purchase agreements (&ldquo;Purchase Agreements&rdquo;) with various investors (collectively, the &ldquo;Investors&rdquo;)
for the private placement of an aggregate of 5,257,267 newly-issued shares of the Company&rsquo;s common stock (the &ldquo;Shares&rdquo;)
at a purchase price of $1.50 per share (the &ldquo;Private Placement&rdquo;). The Investors participating in the Private Placement
were various institutions and the following officers and directors of the Company: Thomas A. Bologna, Chairman of the Board of
Directors and Chief Executive Officer of the Company; David O&rsquo;Toole, Vice President and Chief Financial Officer of the Company;
Denise McNairn, Vice President, General Counsel and Secretary of the Company; Kirk K. Calhoun, Lead Director; Michael Metzger,
Director; Gary D. Nusbaum, Director; Michael Serruya, Director; and David Wurzer, Director. A fund with which Richard van den Broek,
Director, is affiliated also participated in the Private Placement. <FONT STYLE="background-color: white">The final closing of
the Private Placement occurred on February 2, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Private Placement, the Company also entered
into registration rights agreements (&ldquo;Registration Rights Agreements&rdquo;), each dated February 2, 2012, with the Investors
pursuant to which it has agreed to file, within 90 days of the closing of the Private Placement, a registration statement with
the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) to register the Shares for resale, which registration statement
is required to become effective within 180 days following the closing. <FONT STYLE="color: black">The Company also granted the
Investors certain &ldquo;piggyback&rdquo; registration rights, which are triggered if the Company proposes to file a registration
statement for its own account or the account of one or more shareholders </FONT>until the earlier of the sale of all of the Shares
or the Shares becoming eligible for sale under Rule 144(b)(1) without restriction<FONT STYLE="color: black">. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Copies of the form of Purchase Agreement and form of Registration
Rights Agreement entered into with each of the Investors are attached hereto as Exhibits 10.1 and 10.2, respectively, and are incorporated
herein by reference. The foregoing descriptions of the Purchase Agreements and the Registration Rights Agreements do not purport
to be complete and are qualified in their entirety by reference to the full text of Exhibits 10.1 and 10.2, respectively, attached
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 3.02 Unregistered Sale of Equity Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The information set forth in Item 1.01 of this Current Report on
Form 8-K that relates to the unregistered sale of equity securities is incorporated by reference into this Item 3.02.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The aggregate offering price of the Shares is approximately $7,885,900.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The sale of the Shares has not been registered under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). The Shares were sold to accredited investors in reliance upon exemptions
from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. The Shares may
not be offered or sold in the United States absent registration under or exemption from the Securities Act and any applicable state
securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d) Exhibits. The following exhibits are being furnished with this
Current Report on Form 8-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; font-weight: bold">Exhibit Number</TD>
    <TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 83%; font-weight: bold">Document Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.1</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Purchase Agreement.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.2</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Registration Rights Agreement.</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">RESPONSE GENETICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 12%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Dated: February 6, 2012</TD>
    <TD>By:</TD>
    <TD STYLE="text-decoration: none; padding-left: 11pt; border-bottom: Black 1pt solid">/s/ Denise McNairn</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">Name:&nbsp; Denise McNairn</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">Title:&nbsp; Vice President, General Counsel and Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 207pt; text-indent: -207pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v301300_8k.htm", "secsgml_size_bytes": 17184}]
{"company-data": {"conformed-name": "RESPONSE GENETICS INC", "cik": "0001124608", "assigned-sic": "2835", "irs-number": "000000000", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33509", "film-number": "12573733"}, "business-address": {"street1": "1640 MARENGO ST.,", "street2": "6TH FLOOR", "city": "LOS ANGELES,", "state": "CA", "zip": "90033", "phone": "(323) 224-3900"}, "mail-address": {"street1": "1640 MARENGO ST.,", "street2": "6TH FLOOR", "city": "LOS ANGELES,", "state": "CA", "zip": "90033"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February
2, 2012
RESPONSE
GENETICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-1124608
11-3525548
(State or other
(Commission File
(IRS Employer
jurisdiction of
Number)
Identification No.)
incorporation)
1640 Marengo St., 6th Floor
Los Angeles, California 90033
(323) 224-3900
(Address, including zip code, and telephone
number, including area code, of registrant's
principal executive offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On February 2, 2012, Response Genetics, Inc. (the "Company")
entered into purchase agreements ("Purchase Agreements") with various investors (collectively, the "Investors")
for the private placement of an aggregate of 5,257,267 newly-issued shares of the Company's common stock (the "Shares")
at a purchase price of $1.50 per share (the "Private Placement"). The Investors participating in the Private Placement
were various institutions and the following officers and directors of the Company: Thomas A. Bologna, Chairman of the Board of
Directors and Chief Executive Officer of the Company; David O'Toole, Vice President and Chief Financial Officer of the Company;
Denise McNairn, Vice President, General Counsel and Secretary of the Company; Kirk K. Calhoun, Lead Director; Michael Metzger,
Director; Gary D. Nusbaum, Director; Michael Serruya, Director; and David Wurzer, Director. A fund with which Richard van den Broek,
Director, is affiliated also participated in the Private Placement.
The final closing of
the Private Placement occurred on February 2, 2012.
In connection with the Private Placement, the Company also entered
into registration rights agreements ("Registration Rights Agreements"), each dated February 2, 2012, with the Investors
pursuant to which it has agreed to file, within 90 days of the closing of the Private Placement, a registration statement with
the Securities and Exchange Commission (the "SEC") to register the Shares for resale, which registration statement
is required to become effective within 180 days following the closing.
The Company also granted the
Investors certain "piggyback" registration rights, which are triggered if the Company proposes to file a registration
statement for its own account or the account of one or more shareholders
until the earlier of the sale of all of the Shares
or the Shares becoming eligible for sale under Rule 144(b)(1) without restriction
.
Copies of the form of Purchase Agreement and form of Registration
Rights Agreement entered into with each of the Investors are attached hereto as Exhibits 10.1 and 10.2, respectively, and are incorporated
herein by reference. The foregoing descriptions of the Purchase Agreements and the Registration Rights Agreements do not purport
to be complete and are qualified in their entirety by reference to the full text of Exhibits 10.1 and 10.2, respectively, attached
hereto.
Item 3.02 Unregistered Sale of Equity Securities.
The information set forth in Item 1.01 of this Current Report on
Form 8-K that relates to the unregistered sale of equity securities is incorporated by reference into this Item 3.02.
The aggregate offering price of the Shares is approximately $7,885,900.
The sale of the Shares has not been registered under the Securities
Act of 1933, as amended (the "Securities Act"). The Shares were sold to accredited investors in reliance upon exemptions
from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. The Shares may
not be offered or sold in the United States absent registration under or exemption from the Securities Act and any applicable state
securities laws.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are being furnished with this
Current Report on Form 8-K:
Exhibit Number
Document Description
10.1
Form of Purchase Agreement.
10.2
Form of Registration Rights Agreement.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
RESPONSE GENETICS, INC.
Dated: February 6, 2012
By:
/s/ Denise McNairn
Name:  Denise McNairn
Title:  Vice President, General Counsel and Secretary